𝗗𝘆𝘀𝘁𝗿𝗼𝗽𝗵𝗶𝗰 𝗘𝗽𝗶𝗱𝗲𝗿𝗺𝗼𝗹𝘆𝘀𝗶𝘀 𝗕𝘂𝗹𝗹𝗼𝘀𝗮 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗛𝗲𝗮𝗹𝗶𝗻𝗴 𝗦𝗸𝗶𝗻, 𝗛𝗲𝗮𝗹𝗶𝗻𝗴 𝗟𝗶𝗳𝗲
The global DEB treatment market is experiencing significant growth, driven by advancements in gene and cell therapies. With the recent FDA approval of Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for recessive DEB, the landscape is evolving rapidly.
🔗 For more details – https://www.reportprime.com/dy....strophic-epidermolys